Platycodin D inhibits angiogenic vascular mimicry in NSCLC by regulating the eIF4E-mediated RNA methylome  

作　　者：Shuyu Zheng Yanlin Xin Jiamin Lin Zejuan Xie Keyu Cheng Shanshan Wang Wenli Lu Hao Yang Tianming Lu Jun Li Ruogu Qi Yuanyuan Guo 

机构地区：[1]Department of Biochemistry and Molecular Biology,School of Medicine&Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing,210023,China [2]Department of Neurosurgery,The Second Affiliated Hospital,Zhejiang University,Hangzhou,310009,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第1期152-155,共4页药物分析学报（英文版）

基　　金：funded by the National Natural Science Foundation of China(Grant Nos.:82004081 and 52073145);the National Natural Science Foundation of Nanjing University of Chinese Medicine,China(Grant No.:NZY82004081).

摘　　要：The treatment of non-small cell lung cancer(NSCLC)remains a challenge due to tumor evolution during anti-angiogenesis therapies,in which the mechanism of vascular mimicry(VM)is believed to result in ineffective treatment[1].To conquer this challenge,substantial effort has recently been devoted to seeking out natural compounds on account of their multitarget actions.As a traditional herbal medicine,platycodin D(PD)is the major bioactive monomer derived from Platycodon grandiflorum(P.grandiflorum)and is used as an expectorant for pulmonary disease in Asia[2].

关 键 词：NSCLC EIF4E treatment 

分 类 号：R927.1[医药卫生—药学]